Full Text View
Tabular View
No Study Results Posted
Related Studies
Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions
This study has been completed.
First Received: April 1, 2008   Last Updated: April 9, 2008   History of Changes
Sponsors and Collaborators: Par Pharmaceutical, Inc.
AAI Clinic
Information provided by: Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier: NCT00652821
  Purpose

To compare the relative bioavailability of Kali and Ortho-McNeil's products


Condition Intervention Phase
To Determine Bioequivalence Under Fed Conditions.
Drug: Tramadol/ APAP
Drug: Ultracet
Phase I

Study Type: Interventional
Study Design: Randomized, Open Label, Active Control, Crossover Assignment, Bio-equivalence Study
Official Title: To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fed Conditions.

Resource links provided by NLM:


Further study details as provided by Par Pharmaceutical, Inc.:

Primary Outcome Measures:
  • Rate and Extent of Absorption [ Time Frame: 24 Hours ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: May 2002
Study Completion Date: August 2002
Primary Completion Date: August 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Experimental
Subjects received Kali product under fed condition
Drug: Tramadol/ APAP
Tablets 37.5mg /325mg
B: Active Comparator
Subjects received Ortho-Mcneil product under fed conditions
Drug: Ultracet
Tablets, 37.5mg/325mg

Detailed Description:

To compare the relative bioavailability of Kali's Tramadol/APAP 37.5mg/325mg with Ortho-McNeil's Ultracet tablets 37.5mg/325mg

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Males and females between 18 and 45 years of age inclusive
  • Informed of the nature of the study and given written informed consent.
  • Have a body weight within 15% of the appropriate range as defined in the 1983 Metropolitan Life Company tables and weighing at least 100lbs.

Exclusion Criteria:

  • Hypersensitivity to Tramadol/ Acetaminophen, opioids such as morphine and codeine, or related compounds, or a history or seizures.
  • Any history of a clinical condition which might affect drug absorption, metabolism or excretion.
  • Recent history (within one year) of mental illness, drug illness, drug abuse or alcoholism.
  • Donation of greater than 500mL of blood in the past 4 weeks prior to study dosing or difficulty in donating blood.
  • Received an investigational drug within the 4 weeks prior to study dosing.
  • Currently taking any prescription medication, except oral contraceptives, within 7days prior to study dosing or over-the-counter medication within 3 days of the study dosing.
  • This prohibition does not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications as judged by the physician.
  • Tobacco use(>5 cigarettes per day)in the 3 months prior to study dosing.
  • If female, the subject is lactating or has a positive pregnancy test at screening and prior to each of the two treatment periods.
  • Females of child bearing potential must use a medically acceptable method of contraception throughout the entire study period and for one week after the study is completed.
  • Medically acceptable methods of contraception that may be used by the subject and/or her partner are:oral contraceptive, progestin injection or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence.
  • females taking oral contraceptives must have taken them consistently for at least three months prior to receiving study medication.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00652821

Sponsors and Collaborators
Par Pharmaceutical, Inc.
AAI Clinic
Investigators
Principal Investigator: Ralph Scallion AAI Clinic
  More Information

No publications provided

Responsible Party: Par Pharmaceutical, Inc ( Alfred Elvin/ Director Biopharmaceutics )
Study ID Numbers: AAI-US-122
Study First Received: April 1, 2008
Last Updated: April 9, 2008
ClinicalTrials.gov Identifier: NCT00652821     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Par Pharmaceutical, Inc.:
bioequivalence, single-dose, fed

Study placed in the following topic categories:
Malnutrition
Analgesics, Non-Narcotic
Tramadol
Central Nervous System Depressants
Nutrition Disorders
Narcotics
Peripheral Nervous System Agents
Analgesics
Analgesics, Opioid
Acetaminophen

Additional relevant MeSH terms:
Tramadol
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Malnutrition
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Nutrition Disorders
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Acetaminophen
Analgesics, Opioid

ClinicalTrials.gov processed this record on September 10, 2009